We have reported a 27% overall anti-tumor response using i.p. immunotherapy of advanced ovarian carcinoma with autologous, ex vivo expanded, T lymphocytes re-targeted with bi-specific monoclonal antibody OC/TR, combined with soluble OC/TR and low-dose recombinant interleukin-2 (IL-2). This treatment
Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer. Edited by Raymond M. Reilly.
✍ Scribed by Prof. Dr. Thomas L. Mindt; Priv.-Doz. Dr. Dr. med. Flavio Forrer
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 93 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1860-7179
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Ovarian cancer is a highly malignant tumor of mainly postmenopausal women. The long-term prognosis of this malignancy is largely determined by micrometastasis present at the time of second-look surgery. In general, patients face a poor outcome. New radio-immunoscintigraphic methods to target tumor t
Identification of the core residues of the epitope of a monoclonal antibody raised against glycoprotein D of herpes simplex virus type 1 by screening of a random peptide library\* Random peptide libraries (RPL) displayed on the surface of a filamentous bacteriophage can be used to identify peptide l